{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:16:20Z","timestamp":1783617380683,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"1\u00b73\u00b75 project for disciplines of excellence from West China Hospital of Sichuan University","award":["ZYGD23010"],"award-info":[{"award-number":["ZYGD23010"]}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC0746"],"award-info":[{"award-number":["2024NSFSC0746"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    SMARCA4-deficient thoracic undifferentiated tumor is a rare and highly aggressive subtype of lung cancer defined in the 2021 World Health Organization classification. Its scarcity and highly undifferentiated histology limit the availability of representative in vitro models and hinder therapeutic development. In this study, we established a novel cell line, TRI-LC21, from the primary tumor of a patient with lung cancer showing pathological features consistent with this entity. TRI-LC21 exhibited stable proliferation, strong colony-forming ability, and robust tumorigenicity in subcutaneous xenograft models. Xenograft tumors recapitulated the histological features and immunophenotype of the original tumor. Cell line authenticity was confirmed by short tandem repeat profiling, and mycoplasma contamination was excluded. Whole-exome sequencing revealed SMARCA4 loss accompanied by co-mutations in\n                    <jats:italic>TP53<\/jats:italic>\n                    ,\n                    <jats:italic>STK11<\/jats:italic>\n                    ,\n                    <jats:italic>RBM10<\/jats:italic>\n                    , and\n                    <jats:italic>ARHGAP35<\/jats:italic>\n                    . Transcriptome analysis demonstrated decreased expression of epithelial-associated genes and increased expression of stemness- and plasticity-related programs, consistent with an undifferentiated phenotype. Collectively, TRI-LC21 faithfully recapitulates the histological, immunophenotypic, and molecular characteristics of this tumor type and provides a valuable in vitro model for mechanistic investigation and preclinical studies.\n                  <\/jats:p>","DOI":"10.1007\/s13577-026-01418-9","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:26:13Z","timestamp":1783610773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishment and characterization of TRI-LC21: a novel patient-derived cell line of SMARCA4-deficient undifferentiated thoracic tumor"],"prefix":"10.1007","volume":"39","author":[{"given":"Shasha","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanzhi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8823-8602","authenticated-orcid":false,"given":"Yaohui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"11","key":"1418_CR1","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1007\/s00432-021-03586-7","volume":"147","author":"CM Gill","year":"2021","unstructured":"Gill CM, Loewenstern J, Rutland JW, et al. SWI\/SNF chromatin remodeling complex alterations in meningioma. J Cancer Res Clin Oncol. 2021;147(11):3431\u201340.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"1418_CR2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","volume":"45","author":"C Kadoch","year":"2013","unstructured":"Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45(6):592\u2013601.","journal-title":"Nat Genet"},{"issue":"21","key":"1418_CR3","first-page":"6171","volume":"60","author":"AK Wong","year":"2000","unstructured":"Wong AK, Shanahan F, Chen Y, et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 2000;60(21):6171\u20137.","journal-title":"Cancer Res"},{"issue":"1","key":"1418_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1756-8935-3-21","volume":"3","author":"S He","year":"2010","unstructured":"He S, Pirity MK, Wang WL, et al. Chromatin remodeling enzyme Brg1 is required for mouse lens fiber cell terminal differentiation and its denucleation. Epigenetics Chromatin. 2010;3(1):21.","journal-title":"Epigenetics Chromatin"},{"issue":"5","key":"1418_CR5","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.stemcr.2019.03.012","volume":"12","author":"C G\u00fcne\u015f","year":"2019","unstructured":"G\u00fcne\u015f C, Paszkowski-Rogacz M, Rahmig S, et al. Comparative RNAi Screens in Isogenic human stem cells reveal SMARCA4 as a differential regulator. Stem Cell Reports. 2019;12(5):1084\u201398.","journal-title":"Stem Cell Reports"},{"issue":"9","key":"1418_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj5107","volume":"10","author":"JA Hoffman","year":"2024","unstructured":"Hoffman JA, Muse GW, Langer LF, et al. BRG1 establishes the neuroectodermal chromatin landscape to restrict dorsal cell fates. Sci Adv. 2024;10(9):eadj5107.","journal-title":"Sci Adv"},{"issue":"21","key":"1418_CR7","doi-asserted-by":"publisher","first-page":"8223","DOI":"10.1158\/0008-5472.CAN-09-2166","volume":"69","author":"B Weissman","year":"2009","unstructured":"Weissman B, Knudsen KE. Hijacking the chromatin remodeling machinery: impact of SWI\/SNF perturbations in cancer. Cancer Res. 2009;69(21):8223\u201330.","journal-title":"Cancer Res"},{"issue":"4","key":"1418_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2024.02.011","volume":"42","author":"Q Deng","year":"2024","unstructured":"Deng Q, Lakra P, Gou P, et al. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell. 2024;42(4):605-22.e11.","journal-title":"Cancer Cell"},{"issue":"3","key":"1418_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","volume":"17","author":"AG Nicholson","year":"2021","unstructured":"Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2021;17(3):362\u201387.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1418_CR10","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/ng.3399","volume":"47","author":"F Le Loarer","year":"2015","unstructured":"Le Loarer F, Watson S, Pierron G, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet. 2015;47(10):1200\u20135.","journal-title":"Nat Genet"},{"issue":"2","key":"1418_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jtho.2019.10.023","volume":"15","author":"N Rekhtman","year":"2020","unstructured":"Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-Deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15(2):231\u201347.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1418_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.32074\/1591-951X-1272","volume":"117","author":"S Das","year":"2025","unstructured":"Das S, Mishra P, Ahlawat S. Clinicopathological and molecular perspectives on thoracic SMARCA4-deficient undifferentiated tumors and SMARCA4-deficient non-small cell lung carcinomas. Pathologica. 2025;117(5):455\u201367.","journal-title":"Pathologica"},{"issue":"9","key":"1418_CR13","doi-asserted-by":"publisher","first-page":"oyaf266","DOI":"10.1093\/oncolo\/oyaf266","volume":"30","author":"Y Liu","year":"2025","unstructured":"Liu Y, Liu F, Wang C, Yan Y, Yuan X, Chu Q. Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis. Oncologist. 2025;30(9):oyaf266.","journal-title":"Oncologist"},{"issue":"4","key":"1418_CR14","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.21037\/tlcr-24-927","volume":"14","author":"X Zou","year":"2025","unstructured":"Zou X, Zhou X, Guo X, Pan L, Li W. SMARCA4 deficiency: implications for non-small cell lung cancer and management strategies, with relevance to and distinctions from thoracic undifferentiated tumor. Transl Lung Cancer Res. 2025;14(4):1456\u201370.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"1418_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1053\/j.semdp.2021.06.001","volume":"38","author":"A Nambirajan","year":"2021","unstructured":"Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. Semin Diagn Pathol. 2021;38(5):83\u20139.","journal-title":"Semin Diagn Pathol"},{"key":"1418_CR16","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.16923","volume":"12","author":"P Zhou","year":"2024","unstructured":"Zhou P, Fu Y, Tang Y, Jiang L, Wang W. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor. PeerJ. 2024;12:e16923.","journal-title":"PeerJ"},{"issue":"5","key":"1418_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41417-024-00732-4","volume":"31","author":"X Li","year":"2024","unstructured":"Li X, Tian S, Shi H, et al. The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation. Cancer Gene Ther. 2024;31(5):687\u201397.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"1418_CR18","volume":"6","author":"AJ Cooper","year":"2025","unstructured":"Cooper AJ, Arfe A, Ricciuti B, et al. Brief report: clinical characteristics and outcomes of patients with thoracic SMARCA4-deficient undifferentiated tumors. JTO Clin Res Rep. 2025;6(1):100759.","journal-title":"JTO Clin Res Rep"},{"issue":"6","key":"1418_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063237","volume":"25","author":"V Longo","year":"2024","unstructured":"Longo V, Catino A, Montrone M, et al. Treatment of thoracic SMARCA4-deficient undifferentiated tumors: where we are and where we will go. Int J Mol Sci. 2024;25(6):3237.","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"1418_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41379-021-00943-2","volume":"35","author":"N Rekhtman","year":"2022","unstructured":"Rekhtman N. Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol. 2022;35(Suppl 1):36\u201350.","journal-title":"Mod Pathol"},{"key":"1418_CR21","doi-asserted-by":"publisher","first-page":"1813580","DOI":"10.3389\/fonc.2026.1813580","volume":"16","author":"X Yu","year":"2026","unstructured":"Yu X, Cai Y, Wu H, Liu H, Huang B. Thoracic SMARCA4-deficient undifferentiated tumor prone to misdiagnosis as lung adenocarcinoma: a case report and literature review. Front Oncol. 2026;16:1813580.","journal-title":"Front Oncol"},{"issue":"2","key":"1418_CR22","first-page":"128","volume":"40","author":"M Mundada","year":"2024","unstructured":"Mundada M, Mannan KA, Vasu D, Ahmed FKS. Under the microscope: a case report of thoracic smarca4-deficient undifferentiated tumor with review of the literature. Turk Patoloji Derg. 2024;40(2):128\u201333.","journal-title":"Turk Patoloji Derg."},{"issue":"1","key":"1418_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/path.6141","volume":"261","author":"AM Arenas","year":"2023","unstructured":"Arenas AM, Ruiz-Jim\u00e9nez JM, L\u00f3pez-Hidalgo JL, Sanju\u00e1n-Hidalgo J, Medina PP. Defining the first bona fide cell model for SMARCA4-deficient, undifferentiated tumor. J Pathol. 2023;261(1):5\u201310.","journal-title":"J Pathol"},{"issue":"9","key":"1418_CR24","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-23-2360","volume":"30","author":"J Ng","year":"2024","unstructured":"Ng J, Cai L, Girard L, et al. Molecular and pathologic characterization of YAP1-expressing small cell lung cancer cell lines leads to reclassification as SMARCA4-deficient malignancies. Clin Cancer Res. 2024;30(9):1846\u201358.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1418_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/jjco\/hyad175","volume":"54","author":"Y Shinno","year":"2024","unstructured":"Shinno Y, Ohe Y. Thoracic SMARCA4-deficient undifferentiated tumor: current knowledge and future perspectives. Jpn J Clin Oncol. 2024;54(3):265\u201370.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"1418_CR26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.pathol.2023.12.414","volume":"56","author":"AH Cheung","year":"2024","unstructured":"Cheung AH, Wong KY, Chau SL, et al. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant. Pathology. 2024;56(4):504\u201315.","journal-title":"Pathology"},{"issue":"21","key":"1418_CR27","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","volume":"26","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Bandlamudi C, Lavery JA, et al. The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer. Clin Cancer Res. 2020;26(21):5701\u20138.","journal-title":"Clin Cancer Res"},{"key":"1418_CR28","volume":"828","author":"HB Erdem","year":"2024","unstructured":"Erdem HB, Alay MT, \u00d6zdemir Z, et al. Higher TP53 somatic mutation prevalence from liquid biopsy analysis in ever smoker non-small-cell lung cancer patients. Mutat Res. 2024;828:111847.","journal-title":"Mutat Res"},{"key":"1418_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fgene.2016.00085","volume":"7","author":"AR Halvorsen","year":"2016","unstructured":"Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, et al. TP53 mutation spectrum in smokers and never smoking lung cancer patients. Front Genet. 2016;7:85.","journal-title":"Front Genet"},{"issue":"6","key":"1418_CR30","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.21037\/jtd-21-1377","volume":"14","author":"J Malhotra","year":"2022","unstructured":"Malhotra J, Ryan B, Patel M, et al. Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer. J Thorac Dis. 2022;14(6):1772\u201383.","journal-title":"J Thorac Dis"},{"issue":"12","key":"1418_CR31","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.21037\/tlcr-24-552","volume":"13","author":"M Knetki-Wr\u00f3blewska","year":"2024","unstructured":"Knetki-Wr\u00f3blewska M, Wojas-Krawczyk K, Krawczyk P, Krzakowski M. Emerging insights into STK11, KEAP1 and KRAS mutations: implications for immunotherapy in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res. 2024;13(12):3718\u201330.","journal-title":"Transl Lung Cancer Res"},{"key":"1418_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103067","volume":"61","author":"S Zhang","year":"2020","unstructured":"Zhang S, Bao Y, Shen X, et al. RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H. EBioMedicine. 2020;61:103067.","journal-title":"EBioMedicine"},{"key":"1418_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.603932","volume":"11","author":"Y Cao","year":"2021","unstructured":"Cao Y, Di X, Zhang Q, Li R, Wang K. RBM10 regulates tumor apoptosis, proliferation, and metastasis. Front Oncol. 2021;11:603932.","journal-title":"Front Oncol"},{"issue":"10","key":"1418_CR34","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1021\/acs.biochem.7b01242","volume":"57","author":"P Serrano","year":"2018","unstructured":"Serrano P, Hammond JA, Geralt M, W\u00fcthrich K. Splicing site recognition by synergy of three domains in splicing factor RBM10. Biochemistry. 2018;57(10):1563\u20137.","journal-title":"Biochemistry"},{"issue":"6","key":"1418_CR35","doi-asserted-by":"publisher","first-page":"14605","DOI":"10.1080\/21655979.2022.2092677","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun Y, Du R, Shang Y, et al. Rho GTPase-activating protein 35 suppresses gastric cancer metastasis by regulating cytoskeleton reorganization and epithelial-to-mesenchymal transition. Bioengineered. 2022;13(6):14605\u201315.","journal-title":"Bioengineered"},{"key":"1418_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cells8040351","author":"C H\u00e9raud","year":"2019","unstructured":"H\u00e9raud C, Pinault M, Lagr\u00e9e V, Moreau V. p190RhoGAPs, the ARHGAP35- and ARHGAP5-encoded proteins, in health and disease. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8040351.","journal-title":"Cells"},{"issue":"1","key":"1418_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188556","volume":"1876","author":"LJ Hern\u00e1ndez Borrero","year":"2021","unstructured":"Hern\u00e1ndez Borrero LJ, El-Deiry WS. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188556.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"9","key":"1418_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495\u2013509.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1418_CR39","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1158\/0008-5472.CAN-22-1549","volume":"83","author":"Y Bao","year":"2023","unstructured":"Bao Y, Zhang S, Zhang X, et al. RBM10 loss promotes EGFR-driven lung cancer and confers sensitivity to spliceosome inhibition. Cancer Res. 2023;83(9):1490\u2013502.","journal-title":"Cancer Res"},{"issue":"10","key":"1418_CR40","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.tcb.2006.08.006","volume":"16","author":"AJ Ridley","year":"2006","unstructured":"Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 2006;16(10):522\u20139.","journal-title":"Trends Cell Biol"},{"issue":"6","key":"1418_CR41","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.cell.2018.03.051","volume":"173","author":"IT Fiddes","year":"2018","unstructured":"Fiddes IT, Lodewijk GA, Mooring M, et al. Human-specific NOTCH2NL genes affect notch signaling and cortical neurogenesis. Cell. 2018;173(6):1356-69.e22.","journal-title":"Cell"},{"issue":"7","key":"1418_CR42","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/ijc.31169","volume":"142","author":"Y Li","year":"2018","unstructured":"Li Y, Ye Z, Chen S, et al. ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer. Int J Cancer. 2018;142(7):1379\u201391.","journal-title":"Int J Cancer"},{"key":"1418_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1127893","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang C, Guo J. Diverse functions of the inward-rectifying potassium channel Kir5.1 and its relationship with human diseases. Front Physiol. 2023;14:1127893.","journal-title":"Front Physiol"},{"key":"1418_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101039","volume":"57","author":"JF Fu","year":"2024","unstructured":"Fu JF, Hsu CL, Hsu PC. The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)\/2D\/3D culture models harboring EGFR amplification and CDKN2A\/2B homozygous deletions. Neoplasia. 2024;57:101039.","journal-title":"Neoplasia"},{"issue":"Pt 4","key":"1418_CR45","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/brain\/aws045","volume":"135","author":"A Brockschmidt","year":"2012","unstructured":"Brockschmidt A, Trost D, Peterziel H, et al. KIAA1797\/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas. Brain. 2012;135(Pt 4):1027\u201341.","journal-title":"Brain"},{"issue":"16","key":"1418_CR46","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/j.febslet.2008.06.007","volume":"582","author":"M Ikeda","year":"2008","unstructured":"Ikeda M, Kanao Y, Yamanaka M, et al. Characterization of four mammalian 3-hydroxyacyl-CoA dehydratases involved in very long-chain fatty acid synthesis. FEBS Lett. 2008;582(16):2435\u201340.","journal-title":"FEBS Lett"},{"issue":"1","key":"1418_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12672-023-00639-w","volume":"14","author":"J Jiang","year":"2023","unstructured":"Jiang J, Chen Z, Gong J, Han N, Lu H. Thoracic SMARCA4-deficient undifferentiated tumor. Discov Oncol. 2023;14(1):51.","journal-title":"Discov Oncol"},{"issue":"1","key":"1418_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-024-01572-3","volume":"17","author":"E Redin","year":"2024","unstructured":"Redin E, Sridhar H, Zhan YA, et al. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. J Hematol Oncol. 2024;17(1):58.","journal-title":"J Hematol Oncol"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01418-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01418-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01418-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:02:50Z","timestamp":1783616570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01418-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01418-9","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The use of clinical specimens in this study was approved by the Biomedical Ethics Review Committee of West China Hospital, Sichuan University (Approval No. 363). All animal procedures were conducted in accordance with protocols reviewed and approved by the Institutional Animal Care and Use Committee of West China Hospital, Sichuan University (Approval No. 20220323004).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Consent for publication was provided by the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"103"}}